Article
Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.
Cancer chemotherapy and pharmacology - 1 Dec 2015
Deenen Maarten J, Meulendijks Didier, Boot Henk, Legdeur Marie-Cecile J C, Beijnen Jos H, Schellens Jan H M, Cats Annemieke
Abstract excerpt
PURPOSE: The prognosis of gastroesophageal cancer is poor, and current regimens are associated with limited efficacy. The purpose of this study was to explore the safety and preliminary efficacy of docetaxel, oxaliplatin plus capecitabine for advanced cancer of the stomach or the gastroesophageal junction (GEJ). Secondary objectives included pharmacokinetic and pharmacogenetic analyses. METHODS: Patients were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
